Hsiao-Tuan Chao

Chao

Hsiao-Tuan Chao, M.D., Ph.D.

Associate Professor

Positions

Associate Professor
Department of Pediatrics-Division of Neurology and Developmental Neuroscience, Department of Molecular and Human Genetics, Department of Neuroscience
Baylor College of Medicine
Houston, TX, US
Investigator
Jan and Dan Duncan Neurological Research Institute
The Cain Pediatric Neurology Research Foundation Laboratories, Texas Children's Hospital
Houston, TX, US
McNair Scholar
McNair Medical Institute at The Robert and Janice McNair Foundation
Houston, TX
Faculty Senator
Baylor College of Medicine
Associate Program Director, Basic Neuroscience Pathway
Department of Pediatrics
Child Neurology Residency Training Program
Baylor College of Medicine
Houston, TX, US

Addresses

Texas Children's Hospital (Hospital)
Clinical Care Center, Suite 1250
Houston, TX, 77030
United States
Jan and Dan Duncan Neurological Research Institute (Office)
1250 Moursund St
Houston, TX, 77030
United States

Education

Residency at Baylor College of Medicine
Houston, Texas, United States
Pediatric Neurology
Internship at Baylor College of Medicine
06/2013 - Houston, Texas, United States
Pediatrics
MD from Baylor College of Medicine
05/2012 - Houston, Texas, United States
PhD from Baylor College of Medicine
03/2010 - Houston, Texas, United States
Neuroscience
BS from University of Texas at Austin
05/2002 - Austin, Texas, United States
Biochemistry, summa cum laude
BA from University of Texas at Austin
05/2002 - Austin, Texas, United States
Plan II Honors in Liberal Arts, summa cum laude

Honors & Awards

2022 "40 Under 40" List of Autism Researchers
Global Rising Stars in Autism Research https://www.spectrumnews.org/news/40-under-40/
Spectrum News (12/2022)
2022 Young Investigator Award
Department of Pediatrics, Baylor College of Medicine (12/2022)
2022 Inducted to Society for Pediatric Research
The Society for Pediatric Research (SPR) was founded in the 1930s as an academic society committed to fostering the research and career development of investigators engaged in creating new knowledge that advances the health and well-being of children and youth. Since that time, the SPR has emerged as the pre-eminent international society devoted to young investigators in basic science and translational research. Membership is highly competitive, limited to early-stage investigators, and requires demonstration of excellence in child health research through metrics such as extramural peer-reviewed funding and publication of original scientific manuscripts.
Society for Pediatric Research (11/2022)
2020 Philip R. Dodge Young Investigator Award
https://www.bcm.edu/news/chao-awarded-philip-r-dodge-young-investigator-award
Child Neurology Society
2019 Health Care Heroes - Rising Star Award
Houston Business Journal (04/2019)
2017 STAT Wunderkind Award
STAT News (10/2017)
2017 CNS Outstanding Junior Member Award
Child Neurology Society
2017 AAN Neurology Research Scholar
American Academy of Neurology (04/2017)
2017 CNCDP-K12 Scholar
Kennedy Krieger (04/2017)
2011 Top 10 Autism Research Findings of 2010
Chao et al. Nature, 2010
Autism Speaks
2015-2016 Chief Resident
2015-2016 Co-Chief Resident with Dr. Kim Houck for Pediatric Neurology Residency Training Program
BCM Pediatric Neurology Residency
2009 Deborah K. Martin Achievement Award in Biomedical Sciences
Baylor College of Medicine
Robert and Janice McNair Foundation MD/PhD Student Scholar
Baylor College of Medicine (07/2002 - 05/2012)

Professional Interests

  • Pathogenesis of neurodevelopmental and psychiatric disorders
  • Integrate mouse and fruit fly models with human genomics
  • Inhibitory neurons
  • HADD syndrome
  • New disease gene discovery

Professional Statement

As a physician-scientist, my efforts are primarily focused on understanding the genetic and neuro-physiologic underpinnings of neurodevelopmental disorders such as intellectual disability, epilepsy, autism, schizophrenia and other neuropsychiatric conditions. In particular, one emerging theme in the field is that disrupted inhibitory neuronal development and function has been found in association with many neurologic and psychiatric disorders. This would be consistent with the growing body of knowledge that inhibitory neurons are highly diverse and key for virtually all aspects of neurobiology from neural circuit development to information processing. Therefore, elucidating the genetic etiologies of inhibitory neuronal development and function has great potential to advance our understanding of inhibitory neurobiology in health and disease. However, determining the genetic cause is only the first step. The critical advance needed for translation of human genetic studies into clinical applications is to identify the consequences of genetic alterations at the molecular, cellular, neural network and whole-organism levels. This mechanistic dissection of neurodevelopmental disorders bridges molecular function to disease pathogenesis, which is crucial for the development of effective targeted therapeutics. Types of genetic alterations we study in the lab impact transcriptional regulation, protein translation, cell-type specific specification. synapse formation, and neurotransmitter release.

Our goal is to determine the role of cerebro-cerebellar excitatory and inhibitory neuronal dysfunction in the pathogenesis of neurodevelopmental and neuropsychiatric disorders by deciphering how genetic alterations perturb neurotransmission in the brain, impact neural development and lead to abnormal neurologic output. In the Chao Lab, we integrate cross-species approaches in humans to uncover the genetic etiologies of neurodevelopmental disorders, fruit flies to elucidate the molecular pathways and mice to explore the cascade of events in the mammalian brain and develop pre-clinical studies. A variety of approaches and techniques are employed in our laboratory including comprehensive human phenotyping and multiomics studies, genetically engineered mouse and fruit fly models, functional analyses with electrophysiology, imaging, transcriptomics, molecular and cellular assays and behavioral profiling.

In addition to the laboratory research activities, our team leads an Epilepsy Genetics Initiative at the Duncan NRI to identify genetic determinants of undiagnosed developmental and epileptic encephalopathies and we established a multidisciplinary EBF3-related autism spectrum, ataxia, and other neurodevelopmental disorders clinic at TCH. We now follow the largest group of EBF3-related HADDS and 10q26 deletion syndrome patients to date in a single institution and conduct comprehensive phenotypic-genotypic analysis with neurocognitive profiling and neuroimaging. Finally, we are leading a Phase 0 natural history study for STXBP1-related epileptic encephalopathy with the goal of continuing to Phase 1 gene therapy studies. The findings from the clinical studies also inform our laboratory research efforts to understand how gene disruptions alter inhibitory and excitatory neuronal development, perturb neural network activity and lead to cognitive and behavioral abnormalities in neurodevelopmental and psychiatric disorders.

Websites

Chao Laboratory
Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, McNair Medical Institute at The Robert and Janice McNair Foundation
Chao Lab at the NRI
Jan and Dan Duncan Neurological Research Institute

Selected Publications

Projects

Undiagnosed Epilepsy Genetics Initiative
https://redcap.link/epilepsywgs
Research study for patients diagnosed with epilepsy in infancy or early childhood and previous clinical genetic testing is inconclusive. If eligible, families will receive: • No charge whole-genome sequencing (WGS) or research re-analysis of clinical WGS testing. WGS is one of the most advanced genetic testing types available today • No charge fibroblast RNA-sequencing, one of the advanced genetic testing types to interpret the WGS findings
EBF3 related disorders research study
https://redcap.link/ebf3hadds
Hypotonia Ataxia and Delayed Development Syndrome (HADDS) and 10q26-deletion syndrome are neurodevelopmental disorders caused by genetic changes affecting the EBF3 gene located on chromosome 10q26.3. This study aims to improve our understanding of the natural history of EBF3-related neurodevelopmental disorders and the effects on growth and development. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
Chromosome 10q26 disorders research study
https://redcap.link/10q26duplication
10q26-deletion and duplication syndromes are neurodevelopmental disorders caused by genetic changes affecting a region located on chromosome 10q26. This study aims to improve our understanding of the natural history of chromosome 10q26 deletion and duplication neurodevelopmental disorders and the effects on growth and development. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
EIF2AK1 and EIF2AK2 related disorders research study
https://redcap.link/eif2ak2
LEUDEN syndrome is a neurodevelopmental and neurodegenerative disorder with leukodystrophy caused by genetic changes affecting the EIF2AK2 gene. LEMPSAD syndrome is a neurodevelopmental and neurodegenerative disorder with leukodystrophy caused by genetic changes affecting the EIF2AK1 gene. This study aims to improve our understanding of the natural history of these conditions. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
STXBP1-related disorders research study
https://redcap.link/stxbp1survey
The STXBP1 Clinical Trial Ready (STARR), is a study focused on developing clinical trial readiness for STXBP1-related disorders, an epileptic and neurodevelopmental condition caused by changes in the STXBP1 gene. STXBP1-related disorders are one of the most common genetic causes of childhood epilepsies. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
PPFIA3 related disorders research study
https://redcap.link/ppfia3
PPFIA3-related neurodevelopmental disorders is caused by genetic changes affecting the PPFIA3 gene. This study aims to improve our understanding of the natural history of PPFIA3-related neurodevelopmental disorders and the effects on growth and development. Providers or families may visit the RedCap link to answer basic eligibility questions. A research team member will contact you.
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Texas Children's Hospital
Inquiries: Contact chao-lab@bcm.edu https://www.clinicaltrials.gov/study/NCT06983158?term=NCT06983158&rank=1 A Phase 1/2a, Open-Label, Multi-Center, Dose-Escalation Trial to Assess Safety, Tolerability, and Efficacy of a Single Dose of CAP-002 Gene Therapy Administered to Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

Funding

Molecular and Cellular Mechanisms of Cerebellar Dysfunction in Neurodevelopmental disorders
#1R01NS134596 - 01A1
(07/16/2024)
Grant funding from NIH NINDS
McNair Scholar Award
Unrestricted funding from McNair Medical Institute at The Robert and Janice McNair Foundation
DP5 Early Independence Award
#1DP5OD026428
(09/17/2018)
Grant funding from National Institutes of Health
NIH Director's High Risk High Reward Awards Program
Career Award for Medical Scientists
(01/01/2019)
Grant funding from Burroughs Wellcome Fund
Undiagnosed Epilepsy Genetics
(10/01/2020)
Cain Pediatric Neurology Research Foundation
Molecular and Neural Circuit Mechanisms in Autism Spectrum Disorders
(07/01/2021)
Grant funding from Mark A. Wallace Endowment Award
EBF3-related HADDS and 10q26 deletion syndrome
(07/01/2021)
Gift funding from EBF3 HADDS Foundation
STXBP1 Clinical Trial Readiness Natural History Study (STARR)
(07/01/2024)
Grant funding from STXBP1 Foundation

Log In to edit your profile